NEW CLAIM: Simparica: Key Benefits. (sarolaner) chewable tablets ROCK-SOLID FLEA AND TICK PROTECTION FOR DOGS. The only oral product licensed to treat

Similar documents
stronghold PLUS ROCK-SOLID FLEA AND TICK PROTECTION

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

UPDATE ON THE DIAGNOSIS AND MANAGEMENT OF DEMODICOSIS

THE ONLY FLEA AND TICK PROTECTION THAT LASTS UP TO 12 WEEKS * WITH A SINGLE CHEW

Incredible. xng237353_techdetailer4thtick9x12_rsg.indd 1

discover the nextgeneration of flea & tick protection NEW TASTY CHEW ONE CHEW ONCE A MONTH

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Spot-on for Dogs and Cats

EXPECT THE EXTRAORDINARY 1 DOSE. 12 EXTRAORDINARY WEEKS OF FLEA AND TICK PROTECTION.

Kathryn Rook, VMD DACVD Clinical Assistant Professor of Dermatology University of Pennsylvania, School of Veterinary Medicine.

US Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Comparison of Efficacy, Side Effects, and Cost of Isoxasolines and Ivermectin Against Generalized Canine Demodicosis

Summary of Product Characteristics

We re resetting the clock on flea and tick protection.

Doug Carithers 1 William Russell Everett 2 Sheila Gross 3 Jordan Crawford 1

Ectoparasites: preventive plans and innovations in treatment

NEW. paralysis ticks fleas heartworm intestinal worms

A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling canine flea infestations

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.

McKeever Dermatology Clinics

Science and Art of Flea and Tick Control:

Fluralaner (mg) for small cats kg for medium-sized cats > kg for large cats > kg 1.

PETCARE IMMUNIZATION SUPPORT GUARANTEE

Amitraz solution (solution B) consists of the active substance amitraz in a solvent, octyl acetate. No preservative is included in the composition.

A single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Nadja Rohdich *, Rainer KA Roepke and Eva Zschiesche

Irish Medicines Board

Frontline Combo Pack Consult Spot on Dog L SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Excipients Butylhydroxyanisole E320 Butylhydroxytoluene E321

Push flea protection forward

SUMMARY OF PRODUCT CHARACTERISTICS FOR CATS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

MOXIDECTIN SPOT-ON SOLUTION FOR KITTENS AND SMALL CATS. 280 mg/ml FLURALANER 14 mg/ml MOXIDECTIN Also contains: 339 mg/ml DIMETHYLACETAMIDE (solvent)

If empty: Place in trash or offer for recycling if available. CONTAINER HANDLING. Nonrefillable container. Do not reuse or refill this container.

SUMMARY OF PRODUCT CHARACTERSITICS

Dryden et al. Parasites & Vectors (2017) 10:389 DOI /s

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Irish Medicines Board

BRAVECTO HOW TO GET THE BEST RESULTS FOR YOUR DOG

Satisfaction Guarantee Guidelines For Cats and Dogs

SUMMARY OF PRODUCT CHARACTERISTICS

Saunders Solutions in Veterinary Practice Small Animal Dermatology by Anita Patel and Peter Forsythe 2008 Elsevier Ltd. All rights reserved.

COCCIDIOSIS FROM DAY

A monthly spot-on treatment for puppies and dogs.

HEARTWORM DISEASE AND THE DAMAGE DONE

Frontline Combo Pack Consult Spot on Cat SUMMARY OF PRODUCT CHARACTERISTICS

K9 ADVANTIX

SUMMARY OF PRODUCT CHARACTERISTICS. Prinovox 40 mg + 4 mg spot-on solution for small cats and ferrets

A randomized, blinded, controlled USA field study to assess the use of fluralaner tablets in controlling canine flea infestations

Fleas and ticks: how to instigate effective prophylactic regimes

Comparative speed of kill of sarolaner (Simparica ) and afoxolaner (NexGard ) against induced infestations of Rhipicephalus sanguineus s.l.

Systemically and cutaneously distributed ectoparasiticides: a review of the efficacy against ticks and fleas on dogs

MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Powerful Flea and Tick Control Made Just For Cats Helps Consumers Protect their Pets from Harmful Pests

New treatments for manges in dogs? Canine demodicosis. Canine demodicosis. Current approved drug in Canada:

Repellency and acaricidal efficacy of a new combination of fipronil and permethrin against Ixodes ricinus and Rhipicephalus

Daniela Karadzovska 1, Kimberly Chappell 2, Shane Coble 2, Martin Murphy 3, Daniela Cavalleri 3, Scott Wiseman 4, Jason Drake 2* and Steve Nanchen 3

Assessment of the speed of flea kill of lotilaner (Credelio ) throughout the month following oral administration to dogs

A revolution in the parasite control for cats. Dr Anne Bollart Merial Technical & Marketing Manager - Pets Business

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PARASITE TREATMENTS PROVEN PROTECTION FOR DOGS AND CATS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

COMMON MANGE IN DOGS AND CATS days spent on the dog Females burrow tunnels in the stratum corneum to lay eggs

SHE SINGS ALONG TO EVERY SONG...

TO ENSURE ADEQUATE ABSORPTION, ALWAYS ADMINISTER PROGRAM FLAVOR TABS IN CONJUNCTION WITH A NORMAL MEAL.

Ticks Ticks: what you don't know

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT. Fyperix 50 mg Spot-On Solution for Cats

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SATISFACTION GUARANTEED.

ADVANTAGE FOR CATS

Heike Williams 1*, Janina Demeler 2, Janina Taenzler 1, Rainer K.A. Roepke 1, Eva Zschiesche 1 and Anja R. Heckeroth 1

SUMMARY OF PRODUCT CHARACTERISTICS

Please refer to Table 1 Dosage and Treatment Schedule TABLE 1 Species Product Number of Tubes Cats. Rabbits or Advantage 40 for Cats

Neogent 200 mg/g pulvis for oral solution A.U.V. 1 kg

A technical manual for veterinarians

Lénaïg Halos a * Josephus Fourie b Ina Bester b Matthias, Pollmeier a Frédéric Beugnet a

In-home assessment of either topical fluralaner or topical selamectin for flea control in naturally infested cats in West Central Florida, USA

SUMMARY OF PRODUCT CHARACTERISTICS. Active substance: Imidacloprid 40 mg/pipette (0.4 ml of a 10 % solution)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

FREEDOM OF INFORMATION SUMMARY. Rx: U.S. Federal law restricts this drug to use by or on the order of a licen

Irish Medicines Board

FRONTLINE TOP SPOT FOR CATS

Doug Carithers 1 Jordan Crawford 1 William Russell Everett 2 Sheila Gross 3

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

Transcription:

Simparica: Key Benefits NEW CLAIM: The only oral product licensed to treat Demodex canis, Otodectes cynotis and Sarcoptes scabei 1 35 DAYS ROCK-SOLID FLEA AND TICK Persistent flea & tick killing activity for at least 35 days 1 Kills fleas fast before they can lay eggs 1 Only Simparica is indicated for 99% of ticks found in the UK 1,5 Extended ectoparasite spectrum PROTECTION FOR DOGS SIMPARICA (oral tablet) provides immediate and persistent protection from parasites in one convenient monthly dose. Well tolerated in dogs from 8 weeks and 1.3kg 1 Key component in your dermatology solution Palatable tablet readily accepted with or without food For more information, please visit www.simparica.co.uk The only oral product licensed to treat Demodex canis, Otodectes cynotis and Sarcoptes scabei 1 Simparica chewable tablets for dogs contains 5, 1,, 8 or 1mg sarolaner. Indicated for the treatment of flea & tick infestations and the treatment of sarcoptic mange. For information about side effects, precautions, warnings and contra-indications for this product, please refer to the product packaging and package leaflet. Simparica does not require any special storage conditions. Keep out of the sight and reach of children. For animal treatment only. References: 1. Simparica SPC. 2. UK pet owner testing, November 4, 15, prepared by the link group. 3. Six, R.H., Geurden, T., Packianathan, R., Colgan, S., Everett, W.R., Grace, S., Hodge, A., Mahabir, S.P., Myers, M.R., Slootmans, N., Davis, K. (16) Evaluation of the effectiveness of a novel oral formulation of sarolaner (Simparica ) for the treatment and control of fleas on dogs Vet. Parasitol. 222 pp.18-22 4. Six, R.H., Becskei, C., Carter, L., Gale, B., Young, D.R., Mahabir, S.P., Chapin, S. and Myers, M.R. (16) Evaluation on the speed of kill, effects on reproduction, and effectiveness in a simulated infested-home environment of sarolaner (Simparica ) against fleas on dogs Vet. Parasitol. 222 pp. 23-27 5. Calculated from the Health Protection Agency National Tick Recording Scheme, Bristol University tick ID, BADA UK and the Merck manual. 6. Tick distribution map for Ixodes ricinus, as recorded by the PHE Tick Recording Scheme, and the Biological Records Centre (BRC). Added/ updated: 14 October 13. 7. Tick distribution map for Dermacentor reticulatus, as recorded by the HPA Tick Recording Scheme, and the Biological Records Centre (BRC). Added/updated: 14 October 13. 8. Tick distribution map for Ixodes hexagonus, as recorded by the PHE Tick Recording Scheme, and the Biological Records Centre (BRC). Added/updated: 14 October 13. 9. Tick distribution map for Rhipicephalus sanguineus - https://data.nbn.org.uk/taxa/nbnsys39964/grid_map. 1. Geurden, T., Becskei, C., Grace, S., Strube, C., Doherty, P., Liebenberg, J., Mahabir, S.P., Slootmans. N., Lloyd, A. and Six, R.H. (16) Efficacy of a novel oral formulation of sarolaner (Simparica ) against four common tick species infesting dogs in Europe Vet. Parasitol. 222 pp.33-36 11. Six, R.H., Geurden, T, Carter, L., Everett, W.R., McLoughlin, A., Mahabir, S.P., Myers, M.R. and Slootmans, N. (16) Evaluation of the speed of kill of sarolaner (Simparica ) against induced infestations of three species of ticks (Amblyomma maculatum, Ixodex scapularis, Ixodes ricinus) on dogs Vet. Parasitol. 222 pp. 37-42 12. Becskei, C., De Bock, F., Illambas, J., Cherni, J.A., Fourie, J. J., Lane, M., Mahabir, S.P., Six, R. H., (16) Efficacy and safety of a novel oral isoxazoline, sarolaner (Simparica ), for the treatment of sarcoptic mange in dogs Vet. Parasitol. 222 pp. 56 61 13. Becskei, C., Cuppens, O. and Mahabir, S. P. (18), Efficacy and safety of sarolaner in the treatment of canine ear mite infestation caused by Otodectes cynotis: a non-inferiority study. Vet Dermatol. doi:1.1111/ vde.12521 14. Zoetis Study A161C-XC-15-555 15. Zoetis Study A161C-XC-12-83 16. NexGard Spectra SPC. 17. Comfortis SPC. 18. Bravecto SPC. 19. Advocate SPC.. Frontline Combo SPC. The only oral product licensed to treat Demodex canis, Otodectes cynotis and Sarcoptes scabei 1 Kills fleas and ticks for at least 35 days minimising any protection gaps 1 Starts killing fleas from 3 hours and kills 95% within 8 hours 1,4 INDICATED for 99% of UK ticks and kills within 12 hours 1,5 The ideal solution for parasitic management in your dermatology cases For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration. Further information is also available from the Summary of Product Characteristics, or please contact Zoetis UK Ltd, Walton Oaks, Tadworth, Surrey KT 7NS POM-V www.zoetis.co.uk Customer Support: 845 3 834 POM Use medicines responsibly (www.noah.co.uk/responsible) Date of preparation February 18. AH68/18 Adult fleas Flea eggs Ticks Ear mites Demodex Sarcoptic mange

Not all parasiticides are created equally Simparica is a tasty chew for dogs that delivers new advances in flea, tick and mite control, helping to deliver improved client and patient satisfaction. Simparica brings an innovative way to keep on top of fleas, by providing immediate killing activity from 3 hours 4 and persistent killing activity for at least 35 days 1, acting beyond the monthly treatment period. 63% of pet owners confess to have given flea & tick treatment later than when it was due, with the median being 5 days late. 2 Simparica s extended duration of activity helps minimise the potential risk of protection gaps. When choosing an ectoparasiticide key areas to consider include: How does Simparica perform on fleas? Action against the most prevalent species Simparica is effective against both Ctenocephalides felis and Ctenocephalides canis flea infestations in dogs. 1 Simparica was shown to have 1% efficacy for 35 days against the laboratory flea strain KS1. 3 This strain has demonstrated reduced susceptibility to insecticides such as fipronil, imidacloprid and permethrin. 3 1 Percent Reduction in Arithmetic Mean of Live C.felis Counts in Simparica-treated Dogs vs. Placebo 4 Persistent killing activity Simparica provides persistent flea killing activity for at least 35 days 1, acting beyond the monthly treatment period, helping to minimise the potential risk of protection gaps. Immediate and sustained killing activity Simparica has been shown to start killing fleas within 3 hours 4 and kills 95% of fleas within 8 hours for 28 days after product administration. 1 Reducing flea feeding time is key in controlling the clinical signs of FAD. Action against the most prevalent species Persistent killing activity Immediate sustained killing activity % reduction of live C.felis counts 9 8 3 1 1 hour 2 hours 4 hours 8 hours Day Day 7 Day 14 Day 21 Day 28 Day 35 12 hours Prevents environmental flea egg contamination The immediate and persistent flea killing activity of Simparica results in preventing environmental flea egg contamination 1. 1 Simparica efficacy against flea egg laying 4 9 % reduction in C.felis egg counts 8 3 1 Day Day 7 Day 14 Day 21 Day 28 Day 35 Day of count

How does Simparica perform on ticks? Action against the most prevalent species A national government tick surveillance scheme found that Ixodes ricinus (71%), Ixodes hexagonus (27%), Dermacentor reticulatus (1%) and Rhipicephalus sanguineus (<1%) make up 99% of ticks that affect dogs in the UK. 5 Persistent killing activity Simparica provides persistent tick killing activity for at least 35 days, acting beyond the monthly treatment period, helping to minimise the potential risk of protection gaps. 1 Simparica efficacy against ticks 1 Ixodes ricinus 6* Wild and domestic smalllarge mammals, birds and reptiles and amphibians Grassland, moorland, heathland and woodland. Found in suburban/urban areas Lyme disease and Anaplasmosis Dermacentor reticulatus 7* Domestic and wild animals, e.g. dogs, horses, cattle, foxes, hares and hedgehogs Grasslands, pastures and woodlands Babesiosis Ixodes hexagonus 8* Hedgehogs, foxes, ferrets, dogs, cats, rodents and occasionally birds On the host or in the nest. Present in suburban/urban areas Lyme disease and Anaplasmosis Rhipicephalus sanguineus 9* Dogs, cats and foxes but also recorded on cattle, rabbits, hares, hedgehogs and squirrels Kennels and other sheltered places Ehrlichia % reduction in live tick counts 9 8 3 1 Day 2 Day 7 Day 14 Day 21 Day 28 Day 35 Days after treatment Prevalence of ticks in the UK that affect dogs 5 Ixodes ricinus (Sheep Tick) (71%) Ixodes hexagonus (Hedgehog Tick) (27%) Dermacentor reticulatus (Marsh Tick) (1%) Rhipicephalus sanguineus (Brown Dog Tick) (<1%) Other (<1%) D. reticulatus R. sanguineus I. ricinus I. hexagonus Immediate and sustained killing activity Simparica kills ticks (I.ricinus) within 12 hours of attachment for 28 days after product administration. 11 Speed of kill is important in reducing the risk of transmission of tick-borne disease. * Areas with no records do not necessarily represent areas of absence of ticks, but simply that no records have been received from that location.

How does Simparica perform on mites? Simparica: The ONLY oral product licensed to treat sarcoptic mange, ear mite infestations and demodicosis 1 Dogs with natural infestations of Sarcoptes scabiei were given 2 monthly treatments of Simparica, as a result no mites were identified on skin scrapings in any of the dogs post treatment. 12 Simparica aids in the resolution of clinical signs of sarcoptic mange. 12 Clinical signs % of dogs with clinical signs Day Day 14 Day 3 Day PRURITUS 1% 8.1% 42.3% 2.% ERYTHEMA 96.2% 75.5% 38.5% 5.9% PAPULES 94.3%.4% 3.8% 2.% SCALING/ CRUSTING Dogs with S.scabiei treated with 2 monthly treatments of Simparica 12 1% 94.3% 51.9% 11.8% ALOPECIA 1% 1% 88.5% 25.5% Simparica: A single treatment with Simparica is efficacious for the treatment of Otodectes cynotis 13 % of Dogs Without Mites 1 9 8 3 1 76.4 * * 53.9 9.5 63.5 93.3 Simparica: percentage of dogs with Demodex eggs in the skin scrapings 14 In Simparica treated dogs, no Demodex eggs were found after 9 days 66.7 99.4 n=37 n=35 n=15 n=27 n=1 n=9 n=1 n=9 Day 14 Day 3 Day Study Completion n= number of dogs with mites * Simparica non-inferior vs Advocate on day 14 and 3 (not evaluated on day and at study completion) 87.8 Simparica Advocate % of Dogs with Demodex Eggs 1 9 8 3 1 Simparica Advocate Day Day 3 Day Day 9 Day 1 Day 1 Day 18 Study Completion

Simparica: A comprehensive ectoparasite solution in dermatology Part of a comprehensive range of Zoetis dermatological solutions Provides immediate and persistent flea and tick killing activity for at least 35 days, acting beyond the monthly treatment period 1, helping to minimise the potential risk of protection gaps Kills fleas fast, from 3 hours 4 before they can lay eggs, preventing environmental flea egg contamination 1 Ectoparasites Allergies Can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) 1 NEW CLAIM - The only oral product licensed to treat Demodex canis, Otodectes cynotis and Sarcoptes scabei 1 Systemic action provides an ideal solution for dogs that require regular bathing Infections Simparica contains sarolaner. POM-V Apoquel contains oclacitinib, a Janus Kinase (JAK) inhibitor. POM-V Stronghold contains selamectin. POM-V Convenia contains cefovecin sodium. POM-V Synulox contains amoxicillin and clavulanic acid. POM-V Simplicity and satisfaction in a savoury bite Simparica is a tasty, hard chewable tablet readily accepted by dogs Can be given with or without food 1 GREAT-TASTING PROTECTION: Voluntary full consumption within one minute 15 Ideal for dogs that require regular bathing In European field studies Simparica was highly palatable with 93% of doses voluntarily consumed by client owned dogs within 1 minute of being offered 93%

Simparica: The range Bodyweight (kg) Tablet strength (mg sarolaner) Number of tablets to be administered 1.3-2.5 5 One > 2.5-5 1 One > 5-1 One > 1 - One > - 8 One > - 1 One Not all parasiticides are created equally Orals Topicals 3 treatment pack 3 treatment pack 3 treatment pack 1 treatment pack 3 treatment pack 3 treatment pack Simparica: Well tolerated in dogs Fleas % of ticks affecting dogs 5 Simparica 1 NexGard Spectra 16 Comfortis 17 Bravecto 18 Advocate 19 Frontline Combo C. felis 15 days 15 days 84 days 84 days 84 days 168 days Age Weight Adverse Events Margin of Safety Breeds Safety information 1 Can be used in dogs from 8 weeks of age Can be used in dogs from 1.3kg of bodyweight In very rare (less than 1 animal in 1, animals treated, including isolated reports) cases adverse reactions associated with mild and transient gastrointestinal effects such as vomiting and diarrhoea may occur. In very rare cases transient neurological disorders such as tremor, ataxia or convulsion may occur. These signs typically resolve without treatment. In one overdose laboratory study, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum exposure dose and convulsions at 5 times the maximum exposure dose. All dogs recovered without treatment. Simparica is well tolerated in Collies with a deficient multidrug-resistance-protein 1 following single oral administration at 5 times the recommended dose. C. canis 15 days 15 days 168 days Prevents flea egg production Yes Yes Yes Yes Yes Onset of effect Within 8 hrs Within 24 hrs Within.5 hrs Within 8 hrs Within 24 hrs Within 24 hrs Ticks I. ricinus 71% 15 days 84 days 84 days 84 days I. hexagonus 27% 15 days D. reticulatus 1% 15 days 84 days 84 days 84 days R. sanguineus <1% 15 days 84 days 56 days 84 days Onset of effect Within 12 hrs * Within 48 hrs Within 12 hrs^ Within 48 hrs Mites S. scabiei Yes Yes D. canis Yes Yes Concurrent medication Simparica may be used in combination with other routine veterinary medications, including milbemycin oxime, moxidectin and pyrantel pamoate (in these studies efficacy was not investigated). The safety profile of Simparica was extensively studied in both laboratory and field studies, performed worldwide. These studies overall involved more than 3 doses of Simparica administered to over 1 dogs. O. cynotis Yes Yes Age at first use 8 weeks 8 weeks 14 weeks 8 weeks 7 weeks 8 weeks Minimum weight for 28 days after product administration * for 28 days after product administration (I.ricinus) ^ for I.ricinus 1.3kg 2kg 1.3kg 2kg 1kg 2kg